RRMM Patients Treated with IRd: How This Affects Clinicians #ASH19 @TakedaOncology

RRMM Patients Treated with IRd: How This Affects Clinicians #ASH19 @TakedaOncology

ash

5 months
11 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Dawn Marie Stull, PharmD of @TakedaOncology discusses closing the efficacy and effectiveness gap: outcomes in relapsed/refractory multiple myeloma (RRMM) patients (Pts) treated with ixazomib-lenalidomide-dexamethasone (IRd) in routine clinical practice remain comparable to the outcomes reported in the phase 3 tourmaline-MM1 study.

Up Next Autoplay